首页> 美国卫生研究院文献>other >Analyzing Liposomal Drug Delivery Systems in Three-Dimensional Cell Culture Models Using MALDI Imaging Mass Spectrometry
【2h】

Analyzing Liposomal Drug Delivery Systems in Three-Dimensional Cell Culture Models Using MALDI Imaging Mass Spectrometry

机译:使用MALDI成像质谱分析三维细胞培养模型中的脂质体药物递送系统

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cancer chemotherapeutics often fail to reach all diseased cells. To help solve this problem, researchers are investigating novel drug delivery systems. Liposomes are an attractive option due to their low toxicity, high biocompatibility, and potential to carry a large amount of a drug to the tumor site, all while avoiding being eliminated from the body. This study evaluates the penetration of doxorubicin-encased liposomes into three-dimensional cell cultures, or spheroids. Liposomes composed of lipids containing head groups of phosphatidylcholine (PC), phosphatidylethanolamine (PE), and cholesterol were created by extrusion. Doxorubicin is encapsulated within the hydrophilic core of the liposome. The drug is actively released in the spheroid as the lipids bind to cellular lipid bilayers. Spheroids were dosed with liposomal doxorubicin, free doxorubicin, or media control to assess drug distribution over the course of seventy-two hours. Drug penetration was visualized Matrix-Assisted Laser Desorption/Ionization-Imaging Mass Spectrometry (MALDI-IMS) with confirmation by steady state fluorescence microscopy, creating a comprehensive picture of drug distribution. This technique is able to identify both free and liposomal doxorubicin throughout the spheroid after just twelve hours of treatment. Additionally, MALDI-IMS is able to detect three metabolites of doxorubicin, indicating that cells actively metabolize the drug during treatment. Steady state fluorescence microscopy cannot distinguish the drug from its metabolites as they have the same emission spectra. This report summarizes the first study to use MALDI-IMS to analyze drug penetration of a liposomal drug carrier as well as its metabolites.
机译:癌症化学疗法通常无法到达所有患病细胞。为了帮助解决这个问题,研究人员正在研究新型的药物输送系统。脂质体是一种有吸引力的选择,因为它们毒性低,生物相容性高,并且具有将大量药物携带到肿瘤部位的潜力,同时又可以避免从体内清除。这项研究评估了阿霉素包裹的脂质体在三维细胞培养物中的渗透性。通过挤出产生由脂质组成的脂质体,所述脂质包含磷脂酰胆碱(PC),磷脂酰乙醇胺(PE)和胆固醇的头部。阿霉素被包封在脂质体的亲水核内。当脂质与细胞脂质双层结合时,药物在球体中主动释放。给球体服用脂质体阿霉素,游离阿霉素或培养基对照,以评估在72小时内的药物分布。通过稳态荧光显微镜确认,通过基质辅助激光解吸/电离成像质谱(MALDI-IMS)可视化药物渗透,从而创建了完整的药物分布图。治疗仅十二小时后,这项技术就能在整个球体中识别出游离的阿霉素和脂质体阿霉素。此外,MALDI-IMS能够检测阿霉素的三种代谢产物,表明细胞在治疗过程中会积极代谢该药物。稳态荧光显微镜无法将药物与其代谢物区分开,因为它们具有相同的发射光谱。本报告总结了第一项使用MALDI-IMS分析脂质体药物载体及其代谢物的药物渗透的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号